ResMed Inc. (RMD.AX): Well-placed for a re-rate with levers in place; Buy
Report Coverage
- Broker
- Goldman Sachs
- Region
- Global
- Report Type
- Market Report
- Primary Focus
- ResMed Inc. (RMD.AX)
Full Report Document Access
This page is a research report summary and access guidance page. If you are searching for Goldman Sachs ResMed Inc. (RMD.AX) research report PDF or the full report document, use the summary, coverage fields and related links to confirm relevance before requesting VIP access. Full PDF report access is available to VIP members after request confirmation; the PDF is not publicly displayed on this page.
Report Summary
Resmed (RMD.AX) Income Statement Growth Rates (pcp) CAGR June Year End (US$m) FY22A FY23A FY24A FY25A FY26E FY27E FY28E FY22A FY23A FY24A FY25A FY26E FY27E FY28E FY18 - FY23 FY23 - FY28 Devices - US, Canada & Latin America 1,070 1,444 1,523 1,654 1,772 1,903 2,057 23.9% 34.9% 5.4% 8.6% 7.1% 7.4% 8.1% 15.9% 7.3% Devices - Combined Europe, Asia & other markets 797 826 921 1,011 1,133 1,235 1,373 6.7% 3.7% 11.5% 9.7% 12.1% 9.0% 11.2% 6.1% 10.7% Tot
Key Takeaways
- 6% 0.6%
- 5% 0.5%
- 4% 0.4%
- 3% 0.3%
- 2% 0.2%
- 1% 0.1%
Why This Report Matters
Goldman Sachs's 22-page analysis on "ResMed Inc. (RMD.AX): Well-placed for a re-rate with levers in place; Buy" provides institutional-grade insights for investors and professionals seeking to understand current market dynamics and investment implications in this space.
Topics Covered
Companies Mentioned
Who this summary is for
This summary is for users researching the Goldman Sachs ResMed Inc. (RMD.AX) report. It helps users review ResMed Inc. (RMD.AX): Well-placed for a re-rate with levers in place; Buy coverage, key takeaways, and related broker or sector research paths across EV, Healthcare, earnings; Equity Research, June.
Related Search Paths
Use these links to continue through broker, sector and report-type research summaries.